{
    "Trade/Device Name(s)": [
        "Dexcom G6 Pro Continuous Glucose Monitoring System"
    ],
    "Submitter Information": "Dexcom, Inc.",
    "510(k) Number": "K191833",
    "Predicate Device Reference 510(k) Number(s)": [
        "K191450"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QII"
    ],
    "Summary Letter Date": "July 8, 2019",
    "Summary Letter Received Date": "July 9, 2019",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1355"
    ],
    "Regulation Name(s)": [
        "Integrated Continuous Glucose Monitoring System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Dexcom G6 Pro sensor/applicator",
        "Dexcom G6 Pro transmitter",
        "Dexcom G6 Pro mobile application"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement",
        "Glucose oxidase chemical reaction"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "Transmitter",
        "Mobile application"
    ],
    "Document Summary": "FDA 510(k) summary for Dexcom G6 Pro Continuous Glucose Monitoring System for diabetes management and glycemic variability assessment",
    "Indications for Use Summary": "Real-time and retrospective continuous glucose monitoring system for diabetes management and assessment of glycemic variability in persons age 2+ in a home environment under healthcare professional supervision, intended to replace fingerstick glucose testing and interface with digitally connected medical devices",
    "fda_folder": "Clinical Chemistry"
}